In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Mikhail Kosiborod
Speaker
Mikhail Kosiborod
Mikhail Kosiborod Mikhail Kosiborod

St. Luke's Mid America Heart Institute, Kansas City (United States of America)

Specialities : Risk Factors and Prevention , Echocardiography

20 presentations from this speaker

Panel discussion.

Event : ESC Congress 2020

  • Session : The role of glucagon-like peptide-1 receptor agonists in cardiometabolic care
  • Speaker : M Petrie (Glasgow,GB), S Verma (Toronto,CA), M Kosiborod (Kansas,US)
  • Sponsored by Novo Nordisk A/S

Translating knowledge into clinical practice.

Event : ESC Congress 2020

  • Session : The role of glucagon-like peptide-1 receptor agonists in cardiometabolic care
  • Speaker : M Kosiborod (Kansas,US)
  • Sponsored by Novo Nordisk A/S

Treating hyperkalaemia: A step towards achieving optimal RAASi therapy?

Event : HFA Discoveries 2020

  • Session : Treating hyperkalaemia: A step towards achieving optimal RAASi therapy?
  • Speaker : P Ponikowski (Wroclaw,PL), A Coats (Warwickshire,GB), I Pina (Detroit,US), M Kosiborod (Kansas,US), M Crespo-Leiro (La Coruna,ES)
  • Organised by CHANGE IME in partnership with Leicester Diabetes Centre Sponsored by an unrestricted educational grant from AstraZeneca

“Belling the Cat” - Practical guide for cardiologists on Incorporating GLP-1RAs into comprehensive cardiovascular risk reduction

Event : ESC Congress 2019

  • Session : Multi-dimensional glucagon-like peptide-1 receptor agonists — Positioning their role in treatment of type 2 diabetes and cardiovascular disease
  • Speaker : M Kosiborod (Kansas,US)
  • Sponsored by Novo Nordisk A/S

Connecting with the speakers - Questions and answers

Event : ESC Congress 2019

  • Session : Multi-dimensional glucagon-like peptide-1 receptor agonists — Positioning their role in treatment of type 2 diabetes and cardiovascular disease
  • Speaker : L Ryden (Stockholm,SE), S Verma (Toronto,CA), M Kosiborod (Kansas,US)
  • Sponsored by Novo Nordisk A/S

Connecting with the speakers: Questions and Answers

Event : ESC Congress 2019

  • Session : Experts on the spot: exploring new dimensions in glucagon-like peptide-1 receptor agonists and cardiovascular risk
  • Speaker : M Kosiborod (Kansas,US), J Deanfield (,GB), BM Scirica (Boston,US)
  • Sponsored by Novo Nordisk A/S

Lighting the way to the future of heart failure management

Event : ESC Congress 2019

  • Session : Spotlight on the effects of SGLT2 inhibition in heart failure (EBAC accredited)
  • Speaker : M Kosiborod (Kansas,US)
  • Supported by an unrestricted educational grant from AstraZeneca

New dimensions in cardiovascular risk: exploring the latest cardiovascular outcomes trials in type 2 diabetes

Event : ESC Congress 2019

  • Session : Experts on the spot: exploring new dimensions in glucagon-like peptide-1 receptor agonists and cardiovascular risk
  • Speaker : M Kosiborod (Kansas,US)
  • Sponsored by Novo Nordisk A/S

Questions and answers

Event : ESC Congress 2019

  • Session : Spotlight on the effects of SGLT2 inhibition in heart failure (EBAC accredited)
  • Speaker : F Ruschitzka (Zurich,CH), M Bonaca (Boston,US), S Verma (Toronto,CA), M Kosiborod (Kansas,US)
  • Supported by an unrestricted educational grant from AstraZeneca

SGLT2 inhibitors and heart failure: expensive diuretics or added value?

Event : ESC Congress 2019

  • Session : SGLT2 inhibitors and cardiovascular outcomes
  • Speaker : M Kosiborod (Kansas,US)
  • Joint with the European Association for the Study of Diabetes

The management of hyperkalaemia in heart failure: is there room for improvement?

Event : ESC Congress 2019

  • Session : Towards the state-of-the-art potassium control in patients with heart failure: are we there yet? (EBAC accredited)
  • Speaker : M Kosiborod (Kansas,US)
  • Supported by an unrestricted educational grant from AstraZeneca

Towards the state-of-the-art potassium management in heart failure: opportunities and challenges.

Event : ESC Congress 2019

  • Session : Towards the state-of-the-art potassium control in patients with heart failure: are we there yet? (EBAC accredited)
  • Speaker : S Anker (Berlin,DE), M Kosiborod (Kansas,US), M Lainscak (Murska Sobota,SI)
  • Supported by an unrestricted educational grant from AstraZeneca

Panel Q&A - Discussion - Lighting the way: a new path to manage hyperkalaemia.

Event : ESC Congress 2017

  • Session : Lighting the way: a new path to manage hyperkalaemia (EBAC Accredited)
  • Speaker : L Lund (Stockholm,SE), GMC Rosano (London,GB), M Kosiborod (Kansas,US)
  • Sponsored by AstraZeneca

SGLT2 inhibition: the potential to change the heart failure landscape?

Event : Heart Failure 2017

  • Session : Heart failure: what is the potential of SGLT2 inhibition?
  • Speaker : M Kosiborod (Kansas,US)
  • Sponsored by AstraZeneca

SGLT2 inhibition: the potential to change the heart failure landscape? Q&A.

Event : Heart Failure 2017

  • Session : Heart failure: what is the potential of SGLT2 inhibition?
  • Speaker : M Kosiborod (Kansas,US), S Williams (Manchester,GB)
  • Sponsored by AstraZeneca

The new treatment pathway for hyperkalaemia.

Event : ESC Congress 2017

  • Session : Lighting the way: a new path to manage hyperkalaemia (EBAC Accredited)
  • Speaker : M Kosiborod (Kansas,US)
  • Sponsored by AstraZeneca

Hyperkalemia: novel treatment strategies to manage potassium levels.

Event : ESC Congress 2016

  • Session : Optimizing RAAS inhibitor therapy in heart failure and resistant hypertension: challenges and solutions
  • Speaker : M Kosiborod (Kansas,US)
  • Organised by Lorraine University / Course Director: Dr. Faiez Zannad / Supported by an unrestricted educational grant from AstraZeneca

Panel discussion - Optimizing RAAS inhibitor therapy in heart failure and resistant hypertension: challenges and solutions.

Event : ESC Congress 2016

  • Session : Optimizing RAAS inhibitor therapy in heart failure and resistant hypertension: challenges and solutions
  • Speaker : F Zannad (Vandoeuvre,FR), S Anker (Berlin,DE), LM Ruilope (Madrid,ES), M Kosiborod (Kansas,US)
  • Organised by Lorraine University / Course Director: Dr. Faiez Zannad / Supported by an unrestricted educational grant from AstraZeneca

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are